Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 14;54(7):1488-1496.
doi: 10.55730/1300-0144.5935. eCollection 2024.

Outcomes of patients with heart failure in Türkiye

Anıl Şahin  1 , Mehmet Birhan Yilmaz  2 , Ahmet Çelik  3 , İnci Tuğçe Çöllüoğlu  4 , Dilek Ural  5 , Lale Dinç Asarcikli  6 , Sanem Nalbantgil  7 , Emre Demir  7 , Yüksel Çavuşoğlu  8 , Selda Murat  8 , Emine Arzu Kanik  9 , Naim Ata  10 , Mustafa Mahir Ülgü  10 , Şuayip Birinci  11
Affiliations

Outcomes of patients with heart failure in Türkiye

Anıl Şahin et al. Turk J Med Sci. .

Abstract

Background/aim: Despite Türkiye's relatively young population, there is an emerging trend of earlier diagnoses of chronic diseases, including heart failure (HF). This study aims to shed light on survival rates, potential influences of guideline-directed therapies, and sex-based differences necessitating personalized management in HF.

Materials and methods: We conducted a nationwide retrospective cohort analysis of 2,722,151 patients with HF using deidentified data from the Turkish Ministry of Health's national electronic database. That cohort included 2,701,099 adult patients with HF. Adult patients were divided into two groups based on their outcomes as those who were deceased and those who survived and were then compared. Multivariate regression analysis was conducted to identify variables predicting mortality. The patients' hospital admissions and length of hospital stay were analyzed based on survival status and age.

Results: Out of 2,722,151 HF patients, the overall mortality rate was 33.7%, with a difference observed according to sex (32.5% in female patients, 35.0% in male patients). Survival rates at 1, 5, and 7 years after the HF diagnosis were detailed. Deceased HF patients had more comorbidities, higher natriuretic peptides, and lower glomerular filtration rates. Hospitalization patterns varied, with 41% experiencing no hospitalization. The average length of hospital stay in 2022 was 6 days, with sex- and age-specific disparities.

Conclusion: The survival rate of HF in Türkiye is similar to world data. The survival of female patients is better than that of male patients. Increased survival rates can likely be attributed to the widespread use of guideline-directed therapies. Finally, high healthcare utilization is observed, especially in emergency situations.

Keywords: Heart failure; length of stay; mortality; sex.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors declare that there is no conflict of interest regarding the publication of this manuscript.

Figures

Figure 1
Figure 1
Sex-based survival rates in heart failure cases.
Figure 2
Figure 2
Survival based on selected age groups.
Figure 3
Figure 3
Survival rates according to median laboratory parameters in heart failure patients.
Figure 4
Figure 4
Number of hospitalizations throughout the follow-up period.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure. 2022;24(1):4–131. doi: 10.1002/ejhf.2333. - DOI - PubMed
    1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858. doi: 10.1016/s0140-6736(18)32279-7. - DOI - PMC - PubMed
    1. Çavuşoğlu Y, Altay H, Aras D, Çelik A, Ertaş FS, et al. Cost-of-disease of heart failure in Turkey: A Delphi Panel-based analysis of direct and indirect costs. Balkan Medical Journal. 2022;39(4):282–289. doi: 10.4274/balkanmedj.galenos.2022.2022-3-97. - DOI - PMC - PubMed
    1. Norhammar A, Bodegard J, Vanderheyden M, Tangri N, Karasik A, et al. Prevalence, outcomes and costs of a contemporary, multinational population with heart failure. Heart. 2023;109(7):548–556. doi: 10.1136/heartjnl-2022-321702. - DOI - PMC - PubMed
    1. Celik A, Ural D, Sahin A, Colluoglu IT, Kanik EA, et al. Trends in heart failure between 2016 and 2022 in Türkiye (TRends-HF): a nationwide retrospective cohort study of 85 million individuals across entire population of all ages. Lancet Reginal Health Europe. 2023;33:100723. doi: 10.1016/j.lanepe.2023.100723. - DOI - PMC - PubMed